CNBC reports Eli Lilly and Novo Nordisk are both stepping up investment in amylin pathway drugs, viewed as the next-generation core mechanism after GLP-1 obesity therapies. New clinical data shows Lilly’s experimental combination therapy outperformed Zepbound on weight loss, signaling the obesity drug race has entered a new competitive cycle.
The U.S. Food and Drug Administration has officially cleared a blood test for Alzheimer’s disease developed by Roche and Eli Lilly. The test can accurately identify biomarkers of Alzheimer’s through a simple blood sample, eliminating the need for expensive brain scans or invasive cerebrospinal fluid tests. This milestone approval will significantly lower the threshold for early diagnosis, enabling millions of high-risk individuals to receive timely intervention.
Novo Nordisk has sued Eli Lilly, accusing the company of misleading advertising in its weight-loss drug promotion. This lawsuit marks the intensification of competition in the global weight-loss drug market, involving a battle for market share worth tens of billions of dollars.
CVS Restores Coverage for Eli Lilly’s Weight-Loss Drug Zepbound CVS Health, one of America’s largest pharmacy benefit managers, announced it will once again cover Eli Lilly’s weight-loss medication Zepbound (tirzepatide), marking a significant shift in obesity treatment insurance policy in the United States. Zepbound, a GLP-1/GIP dual receptor agonist, has demonstrated remarkable weight-loss results in clinical trials, with patients averaging over 15% body weight reduction within a year. Some participants achieved weight loss exceeding 20%. The drug was initially approved by the FDA for obesity treatment in 2023. ...